SCHEMBL886486

SCHEMBL886486

CNC(=O)c1scc(C)c1Nc1nc(Nc2ccc3c(c2)C(C)(C)NC(=O)CC3)ncc1Cl

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MET P08581 19/20 0.57
INSR P06213 13/20 0.51
ALK Q9UM73 5/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL886533 0.95 MET (0.55) METINSRALK
SCHEMBL16966168 0.87 MET (0.50) METINSRALK
SCHEMBL886277 0.86 MET (0.53) METINSRALK
SCHEMBL886148 0.85 MET (0.78) METINSR
SCHEMBL886426 0.84 MET (0.72) METINSRALK
SCHEMBL2062756 0.82 MET (0.56) METINSRALK
SCHEMBL886626 0.82 MET (0.52) METINSRALK
SCHEMBL16966051 0.82 MET (0.48) METINSRALK
SCHEMBL886502 0.82 MET (0.71) METINSRALK
SCHEMBL886518 0.82 MET (0.69) METINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2684874-B1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors CEPHALON INC (US) 2017-05-17 EP claimed
EP-2222647-B1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS CEPHALON INC (US) 2015-08-05 EP claimed
EP-2222647-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS Cephalon, Inc. (US) 2010-09-01 EP claimed
US-20090221555-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS CEPHALON, INC. (US) 2009-09-03 US claimed
WO-2008051547-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2008-05-02 WO claimed
EP-2684874-B1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors CEPHALON INC (US) 2017-05-17 EP disclosed
EP-2222647-B1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS CEPHALON INC (US) 2015-08-05 EP disclosed
EP-2684874-A1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors Cephalon, Inc. (US) 2014-01-15 EP disclosed
US-8552186-B2 Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors CEPHALON, INC. (US) 2013-10-08 US disclosed
EP-2182088-B1 Atomic layer deposition using metal amidinates HARVARD COLLEGE (US) 2013-07-17 EP disclosed
US-8455672-B2 Atomic layer deposition using metal amidinates PRESIDENT AND FELLOWS OF HARVARD (US) 2013-06-04 US disclosed
US-20120165519-A1 Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors CEPHALON, INC. (US) 2012-06-28 US disclosed
US-7557229-B2 Atomic layer deposition using metal amidinates PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-07-07 US disclosed
EP-1688426-B1 Organometallic complexes and their use as precursors to deposit metal films AIR PROD & CHEM (US) 2008-07-23 EP disclosed
WO-2008051547-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2008-05-02 WO disclosed
EP-1688426-A1 Organometallic complexes and their use as precursors to deposit metal films AIR PRODUCTS AND CHEMICALS, INC. (US) 2006-08-09 EP disclosed
US-20060141155-A1 Atomic layer deposition using metal amidinates HAVARD UNIVERSITY 2006-06-29 US disclosed
US-7064224-B1 Organometallic complexes and their use as precursors to deposit metal films AIR PRODUCTS AND CHEMICALS, INC. (US) 2006-06-20 US disclosed
EP-1563117-A2 ATOMIC LAYER DEPOSITION USING METAL AMIDINATES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2005-08-17 EP disclosed
WO-2004046417-A2 ATOMIC LAYER DEPOSITION USING METAL AMIDINATES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221555-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS ALK, MET, RET MET 2/4885INSR 241/4885ALK 1/4885
US-20120165519-A1 Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors ALK, MET, RET MET 2/4885INSR 241/4885ALK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.